Table 2: Comparative analysis of survivor (SG) and non-survivor (NSG) patients after an episode of ATN according to clinical and laboratory characteristics and outcome.

SG (n = 119) NSG (n = 52)P

Male gender (%)61.361.50.97
Age (years)56.3 ± 16.169.3 ± 12.2<0.0001
ATN-ISS0.26 (0.15–0.45)0.28 (0.19–0.43)
Cardio-vascular disease (%)3757.70.02
Previous chronic renal disease (%)3755.70.008
Diabetes (%)33.642.30.34
Hypertension (%)7069.2
Sepsis (%)25.644.20.001
Type of admission (%)
 (i) Surgical 32.728.8
 (ii) No surgical67.371.2
ICU admission (%)31.928.8
SCr baseline (mg/dL)1 (0.8–1.3)1.3 (1–1.5)0.0003
SCr after 12 months1.3 (1–1.7)1.6 (1.1–1.9)0.08
SCr peak (mg/dL)4.3 (2.6–6.9)3.7 (2.4–6.4)
ATN etiology (%)
 (i) Ischaemic26.939.6
 (ii) Nephrotoxic22.718.9
 (iii) Mix23.518.9
 (iv) Septic26.922.6
ATN severity (%)
 (i) Stage I23.625
 (ii) Stage II24.528.8
 (iii) Stage III50.940.2
Followup (months)18 (11–44.5)10.5 (3–20.5)0.04
Dialysis in-hospital (%)26.017.30.20
Recovery of renal function (%)35.336.50.83

SCr: serum creatinine.
Data showed in %, means ± sd or median (q1–q3).